White & Case Advises Takeda on Divestment of Assets to Hikma and Esteve
February 07, 2025
February 07, 2025
NEW YORK, Feb. 7 -- White and Case, a law firm, issued the following news release:
Global law firm White & Case LLP has advised Takeda Pharmaceutical Company Limited (Takeda) on two deals, the first to divest a portfolio of pharmaceutical products currently licensed and marketed by Hikma Pharmaceuticals PLC (Hikma) for select territories in the Middle East and North Africa (MENA) region, the second to divest the oncological product MEPACT (mifamurtide) to Esteve Pharmaceutical S . . .
Global law firm White & Case LLP has advised Takeda Pharmaceutical Company Limited (Takeda) on two deals, the first to divest a portfolio of pharmaceutical products currently licensed and marketed by Hikma Pharmaceuticals PLC (Hikma) for select territories in the Middle East and North Africa (MENA) region, the second to divest the oncological product MEPACT (mifamurtide) to Esteve Pharmaceutical S . . .